A Phase 2 interventional study of Fx-1006A in Cardiomyopathy, sponsored by Pfizer. Completed at 6 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-01-11.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 230 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 68 under way, 6 of them phase 3. Cardiomyopathies · United States.
Among the 230 studies in Cardiomyopathies with a site in United States, this one is the 74th largest by enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2008, is one of 19 in phase 2, and was the 46th registered.
553 studies on the registry are indexed under Cardiomyopathies; 151 are open to participants now.
Browse Cardiomyopathies studies →56 of the 230 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:
Atrium Therapeutics · Sites in United States
Ages 18–65
Vanderbilt University Medical Center · Sites in United States
Ages 8–18 · Men only
Old Dominion University · Sites in United States
Ages 18–85
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
Lexeo Therapeutics · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Cardiomyopathies studies recruiting now, 70 (61%) set no upper age limit and 17 (15%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
230 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 32 · Phase 3 20 · Phase 4 13
First in 1996; this study’s year is marked. 10 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 51 across 266 interventional studies indexed under Cardiomyopathies.
Median enrollment 42 across the 132 interventional studies, 160 across the 96 observational. Of the 139 that completed or were terminated, 65 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 230 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 5 studies filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
17 of the studies in Cardiomyopathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT04843371Tulane UniversityPPG to Predict Ejection Fraction and Other Echographic Data in the General Population | 2026-12 |
| NCT02855554Medical University of South CarolinaQuantitative Cardiac Parametric Mapping | 2026-12 |
| NCT03534726University of PennsylvaniaEdema and Fibrosis CMR Imaging in Cardiomyopathy | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 230 studies in Cardiomyopathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label, multicenter, international, single-treatment study designed to determine TTR stabilization as well as Fx-1006A safety and tolerability, and its effects on clinical outcomes in patients with V122I or wild-type TTR amyloid cardiomyopathy.
The study will be conducted in two parts. Part 1 will include a six-week dosing period during which all enrolled patients will self-administer oral Fx-1006A 20 mg soft gelatin capsules once daily for six weeks. At Week 6, blood samples will be collected from each patient to determine TTR stabilization. Patients who complete the Week 6 visit will continue taking daily oral Fx 1006A 20 mg for up to a total of 12 months during Part 2 of this study. If it is determined that a patient is not stabilized at Week 6 (based on TTR stabilization data), the patient will be discontinued from the study. Safety and clinical outcomes will be evaluated during Part 2 of this study.
Two whole blood samples for pharmacodynamic assessments (TTR stabilization) and pharmacokinetic assessments (Fx-1006A concentrations as well as calculated steady-state parameters) will be collected at Baseline and Week 6. At Months 6 and 12, two whole blood samples will be collected for pharmacodynamic assessments, and four whole blood samples (two samples per time point) will be collected for pharmacokinetic assessments to be utilized in population pharmacokinetic modeling.
Echocardiography, chest x-ray, cardiac MRI, and 24-hour Holter monitoring will be conducted at Baseline, and Months 6 and 12. Six-minute walk test and quality of life utilizing the Patient Global Assessment, KCCQ, and SF-36 will be assessed at Baseline, and Months 3, 6, and 12. NYHA Classification will be assessed at Baseline, Week 6, and Months 3, 6, and 12. Serum markers of troponin I and T, and NT-pro-BNP levels will be assessed at each study visit.
Safety and tolerability will be assessed throughout the study. Vital signs, 12-lead ECG, blood and urine samples for clinical laboratory tests (serum chemistry, hematology, coagulation panel, and urinalysis), AEs, and concomitant medications (including diuretic usage) will be assessed at each study visit. Abbreviated physical examinations will be conducted at Baseline, Weeks 2 and 6, and Months 3 and 6, and a complete physical examination will be conducted at Month 12.
Clinic visits will be conducted during Screening (Days -30 to -1) and Baseline (Day 0); procedures scheduled for the Baseline visit may be conducted over a period of one week to accommodate patient scheduling. All Baseline procedures must be completed prior to the first self-administered dose on Day 1. Day 1 will be defined as administration of the first dose of study medication, which patients will self-administer at home. During treatment, clinic visits will be conducted at Week 2 (± 2 days), Week 6 (± 1 week), Month 3 (± 1 week), Month 6 (± 2 weeks), and Month 12 (± 2 weeks). Procedures scheduled for the Month 6 and 12 visits may occur over one week during the visit window to accommodate patient scheduling. Monthly telephone contacts (± 1 week of the scheduled date) will be made during months in which no clinical site visits are scheduled (Months 4, 5, 7, 8, 9, 10, and 11) for assessment of AEs and concomitant medications. A final telephone contact to assess AEs and concomitant medication usage will be made 30 days after the last dose of study medication for each patient.
Patients who discontinue from the study at any time will have a final visit performed, including all safety assessments, at the time of discontinuation. Any patient discontinuing after the Month 6 visit will also have all exploratory assessments performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient participated in FoldRx Study Fx-001 (TRACS) OR Patient has documented TTR amyloid cardiomyopathy and Classification of I or II.
TTR amyloid cardiomyopathy is defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fx-1006A
Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Week 6
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
Time frame: Week 6
Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Month 6 and 12
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
Time frame: Month 6, Month 12
Number of Participants With Treatment-Emergent Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to 30 days after the last dose
Number of Participants With Greater Than or Equal to (>=) Grade 3 Treatment-Emergent AEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. On the basis of intensity, grade 3 was referred as severe, grade 4 as life-threatening and grade 5 as death.
Time frame: Baseline up to 30 days after the last dose
Number of Participants With Clinically Significant Treatment-Emergent Echocardiography (ECHO) Findings
ECHO:investigator assessed test to assess cardiac function.ECHO abnormality criteria:any/valvular abnormality,pericardial effusion,abnormal regional wall motion,inferior vena cava respiratory variation,posterior left ventricular wall/septal thickness\>=13 millimeter(mm),right ventricular thickness\>=7mm,ejection fraction \<50%, ratio of early (E) diastolic transmitral flow and atrial(A) contraction velocity (E/A)\>=2, ratio of 'E'to lateral/septal mitral annular velocity (e') (E/e'prime lateral\>15, E/e'prime septal\>15), E deceleration time\<=150 millisecond(msec),Isovolumic relaxation time\<=70msec.
Time frame: Baseline up to Month 12
Number of Participants Discontinuing From The Study Due to Clinically Significant Clinical or Laboratory Adverse Events (AEs)
Time frame: Baseline up to Month 12
Change From Baseline in Echocardiographic (ECHO) Parameters at Month 6 and 12
Echocardiography was used to measure interventricular septal thickness (IVST), posterior left ventricular wall thickness (PLVWT), right ventricular wall thickness (RVWT), left atrial diameter (LAD): anterior-posterior (ant-post), medio-lateral, superior-inferior (sup-inf) and left ventricular end diastolic diameter (LVEDD).
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular Mass (LVM) at Month 6 and 12
LVM was defined as increase in the mass of left ventricle, estimated by echocardiography. Increased LVM was associated with cardiovascular morbidity and mortality.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular Ejection Fraction at Month 6 and 12
Left ventricular ejection fraction (LVEF) was the fraction of the end-diastolic volume (EDV) that is ejected out of left ventricle with each contraction, estimated by echocardiography. EDV is the volume of blood within a ventricle immediately before a contraction.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Doppler Data: E/A and E/e' Ratio at Month 6 and 12
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. Ratio of early (E) diastolic transmitral flow velocity and atrial (A) contraction velocity (E/A) and ratio of the early (E) diastolic transmitral flow velocity to the mitral annular velocity (e') (E/e') were estimated.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Doppler Data: Mitral Deceleration Time at Month 6 and 12
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. The mitral deceleration time was the time taken from the maximum E wave to baseline. E wave arises due to early diastolic filling.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Tissue Doppler- Septal and Lateral Velocity at Month 6 and 12
Tissue Doppler used doppler principles to measure the annular velocities at the lateral and septal areas of the mitral annulus. s': systolic velocity during ejection, e': early diastolic mitral annular velocity, a': late diastolic mitral annular velocity.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Pericardial Effusion at Month 6 and 12
Pericardial effusion was the presence of an abnormal amount of fluid in the pericardial cavity, as determined by echocardiography.
Time frame: Baseline, Month 6, Month 12
Number of Participants With Change From Baseline in Valvular Abnormalities at Month 6 and 12
Valvular abnormalities were those abnormalities (thickening or regurgitation) that involved one or more valves of the heart, determined by echocardiography.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular Anteroseptal, Left Ventricular Inferolateral Wall Thickness and Right Ventricular End Diastolic Free Wall Thickness at Month 6 and 12
Cardiac Magnetic Resonance Imaging (MRI) was done to measure the thickness of left ventricular anteroseptal (LVAS) wall, left ventricular inferolateral (LVIL) wall and right ventricular end diastolic free (RVEDF) wall.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular Mass, Mass of Left Ventricular Myocardium With Amyloidosis, Mass of Left Ventricular Myocardium With Fibrosis/Scar and Right Ventricular End Diastolic Mass at Month 6 and 12
Cardiac MRI was done to measure LVM, mass of left ventricular (LV) myocardium with amyloidosis, mass of LV myocardium with fibrosis/scar and right ventricular end diastolic mass (RVEDM).
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricle End Diastolic Volume, Left Ventricle End Systolic Volume, Left Ventricle Stroke Volume, Right Ventricle End Diastolic Volume, Right Ventricle End Systolic Volume, Right Ventricle Stroke Volume at Month 6 and 12.
Cardiac MRI was done to measure left ventricle end diastolic volume (LVEDV), left ventricle end systolic volume (LVESV), left ventricle stroke volume (LVSV), right ventricle end diastolic volume (RVEDV), right ventricle end systolic volume (RVESV) and right ventricle stroke volume (RVSV).
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular Ejection Fraction and Right Ventricular Ejection Fraction at Month 6 and 12
Cardiac MRI was done to measure: left ventricular ejection fraction (LVEF) was the fraction of the EDV that is ejected out of left ventricle with each contraction and right ventricular ejection fraction (RVEF) was the fraction of the EDV that is ejected out of right ventricle with each contraction. EDV is the volume of blood within a ventricle immediately before a contraction.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular Cardiac Output and Right Ventricular Cardiac Output at Month 6 and 12
Cardiac MRI was done to measure cardiac output, which was the volume of blood being pumped by the heart, in particular by the left or right ventricle in the time interval of one minute.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Percentage of Left Ventricular Myocardial Mass With Amyloidosis and Left Ventricular Myocardial Mass With Fibrosis/Scar at Month 6 and 12
Cardiac MRI was done to measure percentage of LV myocardial mass with amyloidosis and LV myocardial mass with fibrosis/scar. LV myocardial mass with amyloidosis or fibrosis/scar was calculated from the product of the myocardial volume and specific gravity of heart muscle, in participants with amyloidosis or fibrosis/scar, respectively.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in 4 Chamber Interatrial Septal Thickness at Month 6 and 12
Cardiac MRI was done to measure interatrial septal thickness in the 4 chamber view.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in 4 Chamber Left Atrial Dimension and 4 Chamber Right Atrial Dimension at Month 6 and 12
Cardiac MRI was done to measure the left and right atrial dimensions which have diagnostic and prognostic significance in cardiology, in the 4 chamber view.
Time frame: Baseline, Month 6, Month 12
Number of Participants With Atrial Fibrillation/Flutter, Atrial Tachycardia, Non-Sustained Ventricular Tachycardia (NSVT) Beats), Sustained Ventricular Tachycardia (SVT), Sinus Pause at Month 6 and 12
Holter monitor was a machine that recorded the heart rhythms. Holter monitoring abnormalities of atrial fibrillation/flutter (rapid, irregular heart rhythm), atrial tachycardia (rapid cardiac rate), non-sustained ventricular tachycardia (NSVT)\<30 beats, sustained ventricular tachycardia (SVT) \>=30 beats and sinus pause (transient interruption in the sinus rhythm) were recorded.
Time frame: Baseline, Month 6, Month 12
24-Hour Average Heart Rate and Maximium/Minimum Heart Rate
Holter monitor was a machine that recorded the heart rhythms. 24-hour average heart rate and maximium/minimum heart rate was recorded using Holter monitoring.
Time frame: Baseline, Month 6, Month 12
Number of Participants With Complete Heart Block
Complete heart block is the third-degree atrioventricular block in which the impulse generated in the sinoatrial node in the atrium does not propagate to the ventricles.
Time frame: Baseline, Month 6, Month 12
Heart Rate Variability (HRV)- Standard Deviation (SD) Parameters
Holter monitor was a machine that recorded the heart rhythms. HRV time-domain indices were summarized for root-mean-square of successive differences \[RMS SD\] of the R-R intervals (R-R is the interval between successive Rs in the ECG wave) between normal beats (NN), magid standard deviation (Magid SD) of normal to normal R-R intervals and Kleiger standard deviation of normal to normal R-R intervals (Kleiger SD). The term 'NN' is used in place of 'R-R' when the processed beats are normal beats.
Time frame: Baseline, Month 6, Month 12
Heart Rate Variability- Percentage of Successive R-R Intervals With Greater Than 50 Msec Difference Between Normal Beats (pNN50)
Holter monitor was a machine that recorded the heart rhythms. The term 'NN' was used in place of 'R-R' when the processed beats are normal beats. The percentage of successive R-R intervals with greater than 50 msec difference between normal beats was derived by dividing NN50 by the total number of NN intervals (pNN50), where NN50 was the number of interval differences of successive NN intervals greater than 50 msec.
Time frame: Baseline, Month 6, Month 12
Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification at Week 6, Month 3, 6 and 12
NYHA: classified as 'class I' (participants with cardiac disease but without resulting limitations of physical activity), 'class II' (participants with cardiac disease resulting in slight limitation of physical activity), 'class III' (participants with cardiac disease resulting in marked limitation of physical activity), 'class IV' (participants with cardiac disease resulting in inability to carry on any physical activity without discomfort). Participants with change from baseline were classified as 'improved' (positive change), 'no change' or 'worsened' (negative change).
Time frame: Baseline, Week 6, Month 3, Month 6, Month 12
Cardiothoracic (CT) Ratio
Cardiothoracic ratio was defined as the transverse diameter of the heart, compared with that of the thoracic cage, used to help determine enlargement of the heart.
Time frame: Baseline, Month 6, Month 12
Number of Participants With Increased Interstitial Markings and Pleural Effusions
Chest x-ray was done to record the presence of increased interstitial markings (a large number of interstitial markings was indicative of abnormality in the lung) and pleural effusion, which was defined as accumulation of fluid between the layers of tissue that line the lungs and chest cavity.
Time frame: Baseline, Month 6, Month 12
Number of Participants With Change in Patient Global Assessment (PtGA) at Month 3, 6 and 12
Participant's overall quality of life was measured by the PtGA. At baseline participants answered to question: "in general, how do you feel today?" - on a 5-point scale from '1' (excellent) to '5' (poor). At each follow-up visit, participant's answered to question: "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" on a 7-point scale- '1' markedly improved, '2' moderately improved, '3' mildly improved, '4' unchanged, '5' mildly worsened, '6' moderately worsened, '7' markedly worsened.
Time frame: Baseline, Month 3, Month 6, Month 12
Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Score at Month 3, 6 and 12
KCCQ was a 23-item heart failure specific questionnaire quantified in to following 10 summary scores: physical limitation, symptom frequency, symptom severity, and symptom stability, total symptoms, quality of life, social interference, self-efficacy, overall summary and clinical summary. Total score ranged from 0 to 100, where higher scores indicated better functioning, fewer symptoms, and better disease specific quality of life. Summary scores were scaled to range from 0 to 100, with higher scores representing greater disability.
Time frame: Baseline, Month 3, Month 6, Month 12
Change From Baseline in the Short Form 36 (SF-36) at Month 3, 6 and 12
SF-36 was standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Scores for the 8 domains range from 0-100, where higher scores were better (100=highest level of functioning) and reported as 2 summary scores; Mental Component Score (MCS) and Physical Component Score (PCS). The score for a section was an average of the individual question scores, which were scaled 0-100, where higher scores were better.
Time frame: Baseline, Month 3, Month 6, Month 12
Change From Baseline in Troponin I and Troponin T at Week 2, 6, Month 3, 6 and 12
Troponin I and troponin T were the cardiac markers. Troponin I and troponin T were part of the troponin complex, where troponin I was bound to actin in thin myofilaments and troponin T was bound to tropomyosin. Higher level of these markers was indicative of heart damage.
Time frame: Baseline, Week 2, Week 6, Month 3, Month 6, Month 12
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide(NT-proBNP) Levels at Week 2, 6, Month 3, 6 and 12
NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.
Time frame: Baseline, Week 2, Week 6, Month 3, Month 6, Month 12
Change From Baseline in 6-Minute Walk Test (6MWT) at Month 3, 6 and 12
6MWT was used to assess the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.. The distance walked in 6 minutes was categorized as: Level 1: \<300 meter, Level 2: 300-374.9 meter, Level 3: 375-449.9 meter, Level 4: \>=450 meter.
Time frame: Baseline, Month 3, Month 6, Month 12
| Milestone | Tafamidis |
|---|---|
| Started | 35 |
| Completed | 35 |
| Not completed | 0 |
| Milestone | Tafamidis |
|---|---|
| Started | 35 |
| Completed | 32 |
| Not completed | 3 |
| Withdrew: Adverse event | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Death | 1 |
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
| Percentage of participants | Tafamidis |
|---|---|
| Percentage of Participants With Stabilized Transthyretin (TTR Tetramer) at Week 6 | 97.1 (85.1 to 99.9) |
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
| Percentage of participants | Tafamidis |
|---|---|
| Month 6 | 88.2 (72.5 to 96.7) |
| Month 12 | 87.5 (71.0 to 96.5) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| Participants | Tafamidis |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) | 35 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. On the basis of intensity, grade 3 was referred as severe, grade 4 as life-threatening and grade 5 as death.
| Participants | Tafamidis |
|---|---|
| Grade 3 (severe) | 18 |
| Grade 4 (life-threatening) | 1 |
| Grade 5 (death) | 2 |
ECHO:investigator assessed test to assess cardiac function.ECHO abnormality criteria:any/valvular abnormality,pericardial effusion,abnormal regional wall motion,inferior vena cava respiratory variation,posterior left ventricular wall/septal thickness\>=13 millimeter(mm),right ventricular thickness\>=7mm,ejection fraction \<50%, ratio of early (E) diastolic transmitral flow and atrial(A) contraction velocity (E/A)\>=2, ratio of 'E'to lateral/septal mitral annular velocity (e') (E/e'prime lateral\>15, E/e'prime septal\>15), E deceleration time\<=150 millisecond(msec),Isovolumic relaxation time\<=70msec.
| Participants | Tafamidis |
|---|---|
| Any ECHO abnormalities (n=34) | 31 |
| Pericardial effusion (n=28) | 6 |
| Valvular abnormalities- thickening (n=4) | 4 |
| Valvular abnormalities- regurgitation (n=7) | 6 |
| Abnormal regional wall motion (n=19) | 10 |
| Inferior vena cava respiratory variation (n=14) | 7 |
| Left ventricular posterior wall thickness (n=0) | NA |
| Left ventricular septal thickness (n=0) | NA |
| Right ventricular thickness (n=7) | 6 |
| E/A ratio (n=8) | 4 |
| E/e' prime lateral (n=13) | 5 |
| E/e' prime septal (n=6) | 5 |
| Ejection fraction (n=18) | 11 |
| E deceleration time (n=16) | 8 |
| Isovolumic relaxation time (n=16) | 4 |
| Participants | Tafamidis |
|---|---|
| Number of Participants Discontinuing From The Study Due to Clinically Significant Clinical or Laboratory Adverse Events (AEs) | 1 |
Echocardiography was used to measure interventricular septal thickness (IVST), posterior left ventricular wall thickness (PLVWT), right ventricular wall thickness (RVWT), left atrial diameter (LAD): anterior-posterior (ant-post), medio-lateral, superior-inferior (sup-inf) and left ventricular end diastolic diameter (LVEDD).
| millimeter (mm) | Tafamidis |
|---|---|
| IVST: Baseline (n=34) | 20.71 ± 3.58 |
| IVST: Change at Month 6 (n=33) | -0.64 ± 2.41 |
| IVST: Change at Month 12 (n=30) | 0.87 ± 2.52 |
| PLVWT: Baseline (n=34) | 20.20 ± 3.37 |
| PLVWT: Change at Month 6 (n=33) | -0.50 ± 3.83 |
| PLVWT: Change at Month 12 (n=30) | -0.00 ± 2.11 |
| RVWT: Baseline (n=27) | 9.21 ± 2.34 |
| RVWT: Change at Month 6 (n=21) | -0.47 ± 2.47 |
| RVWT: Change at Month 12 (n=20) | 0.26 ± 2.25 |
| LAD (ant-post): Baseline (n=34) | 45.00 ± 6.14 |
| LAD (ant-post): Change at Month 6 (n=33) | -0.40 ± 4.33 |
| LAD (ant-post): Change at Month 12 (n=30) | -0.30 ± 4.19 |
| LAD (medio-lateral): Baseline (n=34) | 44.10 ± 5.56 |
| LAD (medio-lateral): Change at Month 6 (n=32) | 0.70 ± 5.17 |
| LAD (medio-lateral): Change at Month 12 (n=30) | -0.90 ± 6.41 |
| LAD (sup-inf): Baseline (n=34) | 61.50 ± 8.43 |
| LAD (sup-inf): Change at Month 6 (n=32) | 3.00 ± 5.90 |
| LAD (sup-inf): Change at Month 12 (n=30) | 0.80 ± 6.29 |
| LVEDD: Baseline (n=34) | 37.94 ± 5.19 |
| LVEDD: Change at Month 6 (n=33) | 0.45 ± 3.49 |
| LVEDD: Change at Month 12 (n=30) | 0.10 ± 3.41 |
LVM was defined as increase in the mass of left ventricle, estimated by echocardiography. Increased LVM was associated with cardiovascular morbidity and mortality.
| Gram | Tafamidis |
|---|---|
| Baseline (n=34) | 372.50 ± 123.96 |
| Change at Month 6 (n=33) | -19.76 ± 54.38 |
| Change at Month 12 (n=30) | 13.73 ± 77.12 |
Left ventricular ejection fraction (LVEF) was the fraction of the end-diastolic volume (EDV) that is ejected out of left ventricle with each contraction, estimated by echocardiography. EDV is the volume of blood within a ventricle immediately before a contraction.
| Percentage of EDV | Tafamidis |
|---|---|
| Baseline (n=34) | 46.8 ± 14.1 |
| Change at Month 6 (n=33) | -0.4 ± 10.3 |
| Change at Month 12 (n=30) | -3.7 ± 10.4 |
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. Ratio of early (E) diastolic transmitral flow velocity and atrial (A) contraction velocity (E/A) and ratio of the early (E) diastolic transmitral flow velocity to the mitral annular velocity (e') (E/e') were estimated.
| Ratio | Tafamidis |
|---|---|
| E/A ratio: Baseline (n=19) | 2.516 ± 1.084 |
| E/A ratio: Change at Month 6 (n=12) | 0.425 ± 1.117 |
| E/A ratio: Change at Month 12 (n=9) | 0.544 ± 0.575 |
| E/e' ratio: Baseline (n=26) | 16.240 ± 9.089 |
| E/e' ratio: Change at Month 6 (n=15) | 2.217 ± 3.166 |
| E/e' ratio: Change at Month 12 (n=14) | -0.717 ± 5.681 |
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. The mitral deceleration time was the time taken from the maximum E wave to baseline. E wave arises due to early diastolic filling.
| msec | Tafamidis |
|---|---|
| Baseline (n=33) | 152.9 ± 35.3 |
| Change at Month 6 (n=27) | 1.0 ± 37.5 |
| Change at Month 12 (n=27) | -7.1 ± 32.6 |
Tissue Doppler used doppler principles to measure the annular velocities at the lateral and septal areas of the mitral annulus. s': systolic velocity during ejection, e': early diastolic mitral annular velocity, a': late diastolic mitral annular velocity.
| centimeter/second (cm/sec) | Tafamidis |
|---|---|
| Septal s': Baseline (n=23) | 3.70 ± 1.31 |
| Septal s': Change at Month 6 (n=16) | -0.57 ± 0.73 |
| Septal s': Change at Month 12 (n=14) | -0.69 ± 0.77 |
| Septal e': Baseline (n=23) | 3.67 ± 1.60 |
| Septal e': Change at Month 6 (n=17) | -0.09 ± 1.12 |
| Septal e': Change at Month 12 (n=14) | -0.33 ± 1.32 |
| Septal a': Baseline (n=16) | 2.51 ± 1.60 |
| Septal a': Change at Month 6 (n=6) | -0.40 ± 0.43 |
| Septal a': Change at Month 12 (n=6) | -0.42 ± 0.72 |
| Lateral s': Baseline (n=24) | 4.53 ± 1.59 |
| Lateral s': Change at Month 6 (n=14) | -0.50 ± 1.16 |
| Lateral s': Change at Month 12 (n=13) | -0.73 ± 1.22 |
| Lateral e': Baseline (n=26) | 5.09 ± 2.00 |
| Lateral e': Change at Month 6 (n=16) | -0.76 ± 0.80 |
| Lateral e': Change at Month 12 (n=14) | 0.05 ± 0.88 |
| Lateral a': Baseline (n=17) | 3.16 ± 1.94 |
| Lateral a': Change at Month 6 (n=7) | -0.41 ± 0.60 |
| Lateral a': Change at Month 12 (n=9) | 0.06 ± 1.03 |
Pericardial effusion was the presence of an abnormal amount of fluid in the pericardial cavity, as determined by echocardiography.
No measurements were reported for this outcome.
Valvular abnormalities were those abnormalities (thickening or regurgitation) that involved one or more valves of the heart, determined by echocardiography.
No measurements were reported for this outcome.
Cardiac Magnetic Resonance Imaging (MRI) was done to measure the thickness of left ventricular anteroseptal (LVAS) wall, left ventricular inferolateral (LVIL) wall and right ventricular end diastolic free (RVEDF) wall.
| mm | Tafamidis |
|---|---|
| LVAS wall thickness: Baseline (n=18) | 15.808 ± 3.603 |
| LVAS wall thickness: Change at Month 6 (n=18) | 0.810 ± 3.447 |
| LVAS wall thickness: Change at Month 12 (n=15) | 0.813 ± 3.099 |
| LVIL wall thickness: Baseline (n=18) | 15.405 ± 4.616 |
| LVIL wall thickness: Change at Month 6 (n=18) | -1.472 ± 4.333 |
| LVIL wall thickness: Change at Month 12 (n=15) | 1.182 ± 4.782 |
| RVEDF wall thickness: Baseline (n=17) | 10.871 ± 14.001 |
| RVEDF wall thickness: Change at Month 6 (n=17) | -4.501 ± 14.734 |
| RVEDF wall thickness: Change at Month 12 (n=15) | -1.577 ± 4.722 |
Cardiac MRI was done to measure LVM, mass of left ventricular (LV) myocardium with amyloidosis, mass of LV myocardium with fibrosis/scar and right ventricular end diastolic mass (RVEDM).
| Gram | Tafamidis |
|---|---|
| LVM: Baseline (n=18) | 221.599 ± 63.680 |
| LVM: Change at Month 6 (n=18) | 0.557 ± 24.901 |
| LVM: Change at Month 12 (n=15) | 0.119 ± 20.027 |
| LV Amyloidosis: Baseline (n=15) | 63.963 ± 25.614 |
| LV Amyloidosis : Change at Month 6 (n=14) | -13.854 ± 23.921 |
| LV Amyloidosis: Change at Month 12 (n=9) | -4.346 ± 38.364 |
| LV Fibrosis/Scar: Baseline (n=15) | 87.746 ± 60.297 |
| LV Fibrosis/Scar: Change at Month 6 (n=14) | -30.496 ± 52.176 |
| LV Fibrosis/Scar: Change at Month 12 (n=9) | -20.238 ± 64.487 |
| RVEDM: Baseline (n=18) | 65.999 ± 20.296 |
| RVEDM: Change at Month 6 (n=18) | -4.377 ± 20.648 |
| RVEDM: Change at Month 12 (n=15) | 0.215 ± 18.038 |
Cardiac MRI was done to measure left ventricle end diastolic volume (LVEDV), left ventricle end systolic volume (LVESV), left ventricle stroke volume (LVSV), right ventricle end diastolic volume (RVEDV), right ventricle end systolic volume (RVESV) and right ventricle stroke volume (RVSV).
| mL | Tafamidis |
|---|---|
| LVEDV: Baseline (n=18) | 166.673 ± 40.417 |
| LVEDV: Change at Month 6 (n=18) | -0.922 ± 21.164 |
| LVEDV: Change at Month 12 (n=15) | -1.606 ± 20.323 |
| LVESV: Baseline (n=18) | 84.651 ± 29.271 |
| LVESV: Change at Month 6 (n=18) | 3.727 ± 20.963 |
| LVESV: Change at Month 12 (n=15) | 6.479 ± 16.810 |
| LVSV: Baseline (n=18) | 82.022 ± 19.866 |
| LVSV: Change at Month 6 (n=18) | -4.651 ± 21.391 |
| LVSV: Change at Month 12 (n=15) | -8.083 ± 15.614 |
| RVEDV: Baseline (n=18) | 175.124 ± 67.977 |
| RVEDV: Change at Month 6 (n=18) | -4.836 ± 37.879 |
| RVEDV: Change at Month 12 (n=15) | 19.540 ± 39.413 |
| RVESV: Baseline (n=18) | 104.662 ± 48.775 |
| RVESV: Change at Month 6 (n=18) | -1.727 ± 21.438 |
| RVESV: Change at Month 12 (n=15) | 26.250 ± 30.858 |
| RVSV: Baseline (n=18) | 70.478 ± 26.364 |
| RVSV: Change at Month 6 (n=18) | -3.125 ± 26.125 |
| RVSV: Change at Month 12 (n=15) | -6.730 ± 33.975 |
Cardiac MRI was done to measure: left ventricular ejection fraction (LVEF) was the fraction of the EDV that is ejected out of left ventricle with each contraction and right ventricular ejection fraction (RVEF) was the fraction of the EDV that is ejected out of right ventricle with each contraction. EDV is the volume of blood within a ventricle immediately before a contraction.
| Percentage of EDV | Tafamidis |
|---|---|
| LVEF: Baseline (n=18) | 50.176 ± 9.183 |
| LVEF: Change at Month 6 (n=18) | -2.713 ± 13.362 |
| LVEF: Change at Month 12 (n=14) | -3.511 ± 9.063 |
| RVEF: Baseline (n=18) | 42.323 ± 11.949 |
| RVEF: Change at Month 6 (n=18) | -1.756 ± 10.381 |
| RVEF: Change at Month 12 (n=15) | -7.381 ± 12.040 |
Cardiac MRI was done to measure cardiac output, which was the volume of blood being pumped by the heart, in particular by the left or right ventricle in the time interval of one minute.
No measurements were reported for this outcome.
Cardiac MRI was done to measure percentage of LV myocardial mass with amyloidosis and LV myocardial mass with fibrosis/scar. LV myocardial mass with amyloidosis or fibrosis/scar was calculated from the product of the myocardial volume and specific gravity of heart muscle, in participants with amyloidosis or fibrosis/scar, respectively.
| Percentage of LVM | Tafamidis |
|---|---|
| LV Amyloidosis: Baseline (n=15) | 29.069 ± 11.111 |
| LV Amyloidosis: Change at Month 6 (n=14) | -8.200 ± 14.115 |
| LV Amyloidosis: Change at Month 12 (n=9) | -7.017 ± 13.660 |
| LV Fibrosis/Scar: Baseline (n=15) | 36.513 ± 17.789 |
| LV Fibrosis/Scar: Change at Month 6 (n=14) | -10.126 ± 26.397 |
| LV Fibrosis/Scar: Change at Month 12 (n=9) | -8.268 ± 24.884 |
Cardiac MRI was done to measure interatrial septal thickness in the 4 chamber view.
No measurements were reported for this outcome.
Cardiac MRI was done to measure the left and right atrial dimensions which have diagnostic and prognostic significance in cardiology, in the 4 chamber view.
No measurements were reported for this outcome.
Holter monitor was a machine that recorded the heart rhythms. Holter monitoring abnormalities of atrial fibrillation/flutter (rapid, irregular heart rhythm), atrial tachycardia (rapid cardiac rate), non-sustained ventricular tachycardia (NSVT)\<30 beats, sustained ventricular tachycardia (SVT) \>=30 beats and sinus pause (transient interruption in the sinus rhythm) were recorded.
| Participants | Tafamidis |
|---|---|
| Atrial fibrillation/flutter: Baseline (n=33) | 6 |
| Atrial fibrillation/flutter: Month 6 (n=27) | 9 |
| Atrial fibrillation/flutter: Month 12 (n=22) | 9 |
| Atrial tachycardia: Baseline (n=34) | 14 |
| Atrial tachycardia: Month 6 (n=20) | 0 |
| Atrial tachycardia: Month 12 (n=17) | 0 |
| NSVT (<30 beats): Baseline (n=34) | 20 |
| NSVT (<30 beats): Month 6 (n=13) | 3 |
| NSVT (<30 beats): Month 12 (n=12) | 5 |
| SVT (>= 30 beats): Baseline (n=34) | 0 |
| SVT (>= 30 beats): Month 6 (n=33) | 0 |
| SVT (>= 30 beats): Month 12 (n=30) | 1 |
| Sinus pause: Baseline (n=34) | 2 |
| Sinus pause: Month 6 (n=31) | 4 |
| Sinus pause: Month 12 (n=28) | 5 |
Holter monitor was a machine that recorded the heart rhythms. 24-hour average heart rate and maximium/minimum heart rate was recorded using Holter monitoring.
| beats per minute (bpm) | Tafamidis |
|---|---|
| 24-hour average heart rate: Baseline (n=34) | 74.7 ± 7.8 |
| 24-hour average heart rate: Month 6 (n=33) | 73.0 ± 7.2 |
| 24-hour average heart rate: Month 12 (n=30) | 76.6 ± 9.0 |
| Maximum Heart Rate: Baseline (n=34) | 111.7 ± 22.3 |
| Maximum Heart Rate: Month 6 (n=33) | 112.3 ± 17.0 |
| Maximum Heart Rate: Month 12 (n=30) | 121.9 ± 20.4 |
| Minimum Heart Rate: Baseline (n=34) | 56.6 ± 8.0 |
| Minimum Heart Rate: Month 6: (n=33) | 53.1 ± 11.5 |
| Minimum Heart Rate Month 12: (n=30) | 55.3 ± 10.1 |
Complete heart block is the third-degree atrioventricular block in which the impulse generated in the sinoatrial node in the atrium does not propagate to the ventricles.
No measurements were reported for this outcome.
Holter monitor was a machine that recorded the heart rhythms. HRV time-domain indices were summarized for root-mean-square of successive differences \[RMS SD\] of the R-R intervals (R-R is the interval between successive Rs in the ECG wave) between normal beats (NN), magid standard deviation (Magid SD) of normal to normal R-R intervals and Kleiger standard deviation of normal to normal R-R intervals (Kleiger SD). The term 'NN' is used in place of 'R-R' when the processed beats are normal beats.
| msec | Tafamidis |
|---|---|
| HRV- RMS SD: Baseline (n=30) | 75.9 ± 71.0 |
| HRV- RMS SD: Month 6 (n=26) | 88.1 ± 71.0 |
| HRV- RMS SD: Month 12 (n=21) | 91.7 ± 72.1 |
| HRV- Magid SD: Baseline (n=31) | 58.3 ± 42.1 |
| HRV- Magid SD: Month 6 (n=33) | 82.6 ± 55.5 |
| HRV- Magid SD: Month 12 (n=30) | 78.6 ± 50.1 |
| HRV- Kleiger SD: Baseline (n=31) | 100.3 ± 49.1 |
| HRV- Kleiger SD: Month 6 (n=33) | 123.9 ± 52.8 |
| HRV- Kleiger SD: Month 12 (n=30) | 120.3 ± 48.7 |
Holter monitor was a machine that recorded the heart rhythms. The term 'NN' was used in place of 'R-R' when the processed beats are normal beats. The percentage of successive R-R intervals with greater than 50 msec difference between normal beats was derived by dividing NN50 by the total number of NN intervals (pNN50), where NN50 was the number of interval differences of successive NN intervals greater than 50 msec.
| Percentage of intervals | Tafamidis |
|---|---|
| Baseline (n=30) | 19.7 ± 25.5 |
| Month 6 (n=26) | 29.3 ± 32.7 |
| Month 12 (n=21) | 23.6 ± 27.3 |
NYHA: classified as 'class I' (participants with cardiac disease but without resulting limitations of physical activity), 'class II' (participants with cardiac disease resulting in slight limitation of physical activity), 'class III' (participants with cardiac disease resulting in marked limitation of physical activity), 'class IV' (participants with cardiac disease resulting in inability to carry on any physical activity without discomfort). Participants with change from baseline were classified as 'improved' (positive change), 'no change' or 'worsened' (negative change).
| Participants | Tafamidis |
|---|---|
| Baseline: Class I (n=35) | 5 |
| Baseline: Class II (n=35) | 28 |
| Baseline: Class III (n=35) | 2 |
| Baseline: Class IV (n=35) | 0 |
| Change at Month 3: improved (n=34) | 5 |
| Change at Month 3: no change (n=34) | 23 |
| Change at Month 3: worsened (n=34) | 6 |
| Change at Month 6: improved (n=34) | 1 |
| Change at Month 6: no change (n=34) | 27 |
| Change at Month 6: worsened (n=34) | 6 |
| Change at Month 12: improved (n=32) | 4 |
| Change at Month 12: no change (n=32) | 20 |
| Change at Month 12: worsened (n=32) | 8 |
Cardiothoracic ratio was defined as the transverse diameter of the heart, compared with that of the thoracic cage, used to help determine enlargement of the heart.
| Ratio | Tafamidis |
|---|---|
| Baseline | 55.130 ± 6.075 |
| Month 6 | 56.620 ± 5.904 |
| Month 12 | 57.830 ± 5.366 |
Chest x-ray was done to record the presence of increased interstitial markings (a large number of interstitial markings was indicative of abnormality in the lung) and pleural effusion, which was defined as accumulation of fluid between the layers of tissue that line the lungs and chest cavity.
| Participants | Tafamidis |
|---|---|
| Increased interstitial markings: Baseline | 11 |
| Increased interstitial markings: Month 6 | 4 |
| Increased interstitial markings: Month 12 | 4 |
| Pleural effusion- right: Baseline | 9 |
| Pleural effusion- right: Month 6 | 8 |
| Pleural effusion- right: Month 12 | 6 |
| Pleural effusion- left: Baseline | 6 |
| Pleural effusion- left: Month 6 | 5 |
| Pleural effusion- left: Month 12 | 4 |
| Pleural effusion- bilateral: Baseline | 6 |
| Pleural effusion- bilateral: Month 6 | 4 |
| Pleural effusion- bilateral: Month 12 | 3 |
Participant's overall quality of life was measured by the PtGA. At baseline participants answered to question: "in general, how do you feel today?" - on a 5-point scale from '1' (excellent) to '5' (poor). At each follow-up visit, participant's answered to question: "How do you feel today as compared to when we talked with you at your last clinic visit for this study?" on a 7-point scale- '1' markedly improved, '2' moderately improved, '3' mildly improved, '4' unchanged, '5' mildly worsened, '6' moderately worsened, '7' markedly worsened.
| Participants | Tafamidis |
|---|---|
| Excellent: Baseline (n=33) | 5 |
| Very good: Baseline (n=33) | 14 |
| Good: Baseline (n=33) | 12 |
| Fair: Baseline (n=33) | 2 |
| Poor: Baseline (n=33) | 0 |
| Markedly improved: Month 3 (n=34) | 2 |
| Moderately improved: Month 3 (n=34) | 7 |
| Mildly improved: Month 3 (n=34) | 6 |
| Unchanged: Month 3 (n=34) | 15 |
| Mildly worsened: Month 3 (n=34) | 2 |
| Moderately worsened: Month 3 (n=34) | 2 |
| Markedly worsened: Month 3 (n=34) | 0 |
| Markedly improved: Month 6 (n=34) | 3 |
| Moderately improved: Month 6 (n=34) | 4 |
| Mildly improved: Month 6 (n=34) | 3 |
| Unchanged: Month 6 (n=34) | 16 |
| Mildly worsened: Month 6 (n=34) | 8 |
| Moderately worsened: Month 6 (n=34) | 0 |
| Markedly worsened: Month 6 (n=34) | 0 |
| Markedly improved: Month 12 (n=32) | 0 |
| Moderately improved: Month 12 (n=32) | 5 |
| Mildly improved: Month 12 (n=32) | 3 |
| Unchanged: Month 12 (n=32) | 16 |
| Mildly worsened: Month 12 (n=32) | 4 |
| Moderately worsened: Month 12 (n=32) | 3 |
| Markedly worsened: Month 12 (n=32) | 1 |
KCCQ was a 23-item heart failure specific questionnaire quantified in to following 10 summary scores: physical limitation, symptom frequency, symptom severity, and symptom stability, total symptoms, quality of life, social interference, self-efficacy, overall summary and clinical summary. Total score ranged from 0 to 100, where higher scores indicated better functioning, fewer symptoms, and better disease specific quality of life. Summary scores were scaled to range from 0 to 100, with higher scores representing greater disability.
| Units on a scale | Tafamidis |
|---|---|
| Physical limitations: Baseline (n=35) | 72.9 ± 20.8 |
| Physical limitations: Change at Month 3 (n=33) | -2.7 ± 15.0 |
| Physical limitations: Change at Month 6 (n=34) | -0.4 ± 13.6 |
| Physical limitations: Change at Month 12 (n=31) | -8.1 ± 18.8 |
| Symptom stability: Baseline (n=35) | 55.7 ± 13.7 |
| Symptom stability: Change at Month 3 (n=34) | 3.7 ± 27.6 |
| Symptom stability: Change at Month 6 (n=34) | -5.9 ± 25.4 |
| Symptom stability: Change at Month 12 (n=31) | 0.0 ± 22.4 |
| Symptom frequency: Baseline (n=35) | 73.8 ± 22.2 |
| Symptom frequency: Change at Month 3 (n=34) | -1.8 ± 18.5 |
| Symptom frequency: Change at Month 6 (n=34) | -2.5 ± 15.9 |
| Symptom frequency: Change at Month 12 (n=31) | -6.0 ± 18.2 |
| Symptom burden: Baseline (n=35) | 76.9 ± 18.1 |
| Symptom burden: Change at Month 3 (n=34) | -4.0 ± 18.3 |
| Symptom burden: Change at Month 6 (n=34) | -4.7 ± 15.2 |
| Symptom burden: Change at Month 12 (n=31) | -8.6 ± 19.2 |
| Total symptom: Baseline (n=35) | 75.4 ± 19.2 |
| Total symptom: Change at Month 3 (n=34) | -2.9 ± 16.9 |
| Total symptom: Change at Month 6 (n=34) | -3.6 ± 14.3 |
| Total symptom: Change at Month 12 (n=31) | -7.3 ± 18.2 |
| Self-efficacy: Baseline (n=35) | 85.7 ± 19.0 |
| Self-efficacy: Change at Month 3 (n=33) | 1.9 ± 14.7 |
| Self-efficacy: Change at Month 6 (n=34) | 1.1 ± 13.5 |
| Self-efficacy: Change at Month 12 (n=31) | 1.6 ± 16.7 |
| Quality of life: Baseline (n=35) | 66.9 ± 19.2 |
| Quality of life: Change at Month 3 (n=34) | 1.0 ± 18.2 |
| Quality of life: Change at Month 6 (n=34) | -0.2 ± 14.4 |
| Quality of life: Change at Month 12 (n=31) | -4.0 ± 20.4 |
| Social limitation: Baseline (n=33) | 69.3 ± 25.4 |
| Social limitation: Change at Month 3 (n=30) | -0.6 ± 19.6 |
| Social limitation: Change at Month 6 (n=31) | -2.4 ± 22.6 |
| Social limitation: Change at Month 12 (n=27) | -9.2 ± 25.2 |
| Overall summary: Baseline (n=35) | 71.4 ± 18.8 |
| Overall summary: Change at Month 3 (n=34) | -0.8 ± 14.9 |
| Overall summary: Change at Month 6 (n=34) | -1.5 ± 12.4 |
| Overall summary: Change at Month 12 (n=31) | -6.9 ± 18.0 |
| Clinical summary: Baseline (n=35) | 74.1 ± 18.9 |
| Clinical summary: Change at Month 3 (n=34) | -2.0 ± 15.9 |
| Clinical summary: Change at Month 6 (n=34) | -2.0 ± 11.9 |
| Clinical summary: Change at Month 12 (n=31) | -7.7 ± 17.9 |
SF-36 was standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Scores for the 8 domains range from 0-100, where higher scores were better (100=highest level of functioning) and reported as 2 summary scores; Mental Component Score (MCS) and Physical Component Score (PCS). The score for a section was an average of the individual question scores, which were scaled 0-100, where higher scores were better.
| Units on a scale | Tafamidis |
|---|---|
| PCS: Baseline (n=33) | 41.0 ± 9.69 |
| PCS: Change at Month 6 (n=32) | -1.4 ± 5.87 |
| PCS: Change at Month 12 (n=29) | -2.4 ± 7.58 |
| MCS: Baseline (n=33) | 52.7 ± 9.51 |
| MCS: Change at Month 6 (n=32) | 0.3 ± 8.40 |
| MCS: Change at Month 12 (n=29) | -2.0 ± 9.56 |
| Physical functioning: Baseline (n=34) | 37.7 ± 11.28 |
| Physical functioning: Change at Month 6 (n=33) | -0.7 ± 6.89 |
| Physical functioning: Change at Month 12 (n=29) | -2.0 ± 7.34 |
| Role-physical: Baseline (n=35) | 42.3 ± 10.84 |
| Role-physical: Change at Month 6 (n=34) | -1.4 ± 7.12 |
| Role-physical: Change at Month 12 (n=30) | -3.5 ± 9.29 |
| Bodily pain: Baseline (n=35) | 53.2 ± 9.57 |
| Bodily pain: Change at Month 6 (n=34) | -4.0 ± 8.74 |
| Bodily pain: Change at Month 12 (n=30) | -3.2 ± 11.81 |
| General health: Baseline (n=35) | 41.5 ± 9.33 |
| General health: Change at Month 6 (n=34) | 0.7 ± 9.23 |
| General health: Change at Month 12 (n=30) | -1.6 ± 8.44 |
| Vitality: Baseline (n=34) | 50.6 ± 8.11 |
| Vitality: Change at Month 6 (n=33) | -0.1 ± 6.83 |
| Vitality: Change at Month 12 (n=30) | -2.2 ± 7.83 |
| Social functioning: Baseline (n=35) | 48.4 ± 9.84 |
| Social functioning: Change at Month 6 (n=34) | -2.9 ± 9.23 |
| Social functioning: Change at Month 12 (n=30) | -3.6 ± 11.40 |
| Role-emotional: Baseline (n=35) | 45.2 ± 11.71 |
| Role-emotional: Change at Month 6 (n=34) | 0.6 ± 12.26 |
| Role-emotional: Change at Month 12 (n=30) | -3.0 ± 12.53 |
| Mental health: Baseline (n=34) | 53.3 ± 8.50 |
| Mental health: Change at Month 6 (n=33) | 0.3 ± 5.01 |
| Mental health: Change at Month 12 (n=30) | -1.1 ± 7.50 |
Troponin I and troponin T were the cardiac markers. Troponin I and troponin T were part of the troponin complex, where troponin I was bound to actin in thin myofilaments and troponin T was bound to tropomyosin. Higher level of these markers was indicative of heart damage.
| nanogram/milliliter (ng/mL) | Tafamidis |
|---|---|
| Troponin I: Baseline (n=33) | 0.135 ± 0.080 |
| Troponin I: Change at Week 2 (n=35) | 0.003 ± 0.060 |
| Troponin I: Change at Week 6 (n=35) | -0.000 ± 0.055 |
| Troponin I: Change at Month 3 (n=34) | 0.008 ± 0.057 |
| Troponin I: Change at Month 6 (n=34) | -0.016 ± 0.051 |
| Troponin I: Change at Month 12 (n=32) | 0.016 ± 0.064 |
| Troponin T: Baseline (n=33) | 0.044 ± 0.037 |
| Troponin T: Change at Week 2 (n=35) | 0.001 ± 0.025 |
| Troponin T: Change at Week 6 (n=35) | 0.006 ± 0.020 |
| Troponin T: Change at Month 3 (n=34) | 0.008 ± 0.021 |
| Troponin T: Change at Month 6 (n=33) | 0.002 ± 0.020 |
| Troponin T: Change at Month 12 (n=32) | 0.012 ± 0.023 |
NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.
| picogram/mL (pg/mL) | Tafamidis |
|---|---|
| Baseline (n=33) | 4934.2 ± 4324.9 |
| Change at Week 2 (n=35) | -1.6 ± 1349.1 |
| Change at Week 6 (n=35) | 295.0 ± 1632.0 |
| Change at Month 3 (n=34) | 102.8 ± 1998.0 |
| Change at Month 6 (n=33) | 111.6 ± 2032.4 |
| Change at Month 12 (n=31) | 958.2 ± 3178.0 |
6MWT was used to assess the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.. The distance walked in 6 minutes was categorized as: Level 1: \<300 meter, Level 2: 300-374.9 meter, Level 3: 375-449.9 meter, Level 4: \>=450 meter.
| meters | Tafamidis |
|---|---|
| Distance walked: Baseline (n=34) | 354.5 ± 126.0 |
| Distance walked: Change at Month 3 (n=31) | -4.6 ± 63.1 |
| Distance walked: Change at Month 6 (n=33) | 3.9 ± 58.2 |
| Distance walked: Change at Month 12 (n=28) | -11.2 ± 76.4 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tafamidis | — | 15/35 (42.9%) | 34/35 (97.1%) |
| Event | Tafamidis |
|---|---|
| Cardiac failure congestiveCardiac disorders | 9/35 |
| Atrial fibrillationCardiac disorders | 3/35 |
| FallInjury, poisoning and procedural complications | 3/35 |
| Cardiac failureCardiac disorders | 2/35 |
| SyncopeNervous system disorders | 2/35 |
| Supraventricular tachycardiaCardiac disorders | 1/35 |
| Ventricular tachycardiaCardiac disorders | 1/35 |
| AmyloidosisImmune system disorders | 1/35 |
| CellulitisInfections and infestations | 1/35 |
| Escherichia sepsisInfections and infestations | 1/35 |
| Event | Tafamidis |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/35 |
| FatigueGeneral disorders | 8/35 |
| DiarrhoeaGastrointestinal disorders | 7/35 |
| DizzinessNervous system disorders | 7/35 |
| Oedema peripheralGeneral disorders | 6/35 |
| Upper respiratory tract infectionInfections and infestations | 6/35 |
| Weight decreasedInvestigations | 6/35 |
| Dizziness posturalNervous system disorders | 6/35 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 6/35 |
| ConstipationGastrointestinal disorders | 5/35 |
| Age Continuous(Years) | Tafamidis |
|---|---|
| Mean | 76.4 ± 4.7 |
| Sex: Female, Male(Participants) | Tafamidis |
|---|---|
| Female | 3 |
| Male | 32 |
The record gives a start of Aug 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 2 years 11 months after primary completion. A results delay was requested in Oct 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafamidis